Outsourced Pharma White Papers

  1. Optimizing Safety Measures For rAAV Therapies 10/11/2024

    Explore common process-related impurities found in recombinant Adeno-Associated Virus (rAAV) vectors and the analytical testing methods used for these residuals.

  2. EMA Support For Rare Disease Therapies 6/10/2025

    Review how the EMA supports rare disease drug development through regulatory and financial incentives for therapies that meet strict eligibility and ongoing compliance criteria.

  3. What FDA CRLs Reveal About CCIT 4/14/2026

    FDA rejection letters show common CCIT gaps — low sensitivity and incomplete validation. Spotting these trends helps teams strengthen integrity testing and avoid approval delays.

  4. Calcium Carbonate Vs Titanium Dioxide: Why Particle Engineering Matter 11/10/2025

    Discover how particle-engineered calcium carbonate offers a viable alternative to titanium dioxide in tablet coatings, achieving good opacity, process efficiency, and comparable tablet properties.

  5. Unlocking Durable Allogeneic Cell Therapy 5/13/2026

    Advances in genome engineering and immune evasion are enabling scalable, durable allogeneic cell therapies, overcoming rejection challenges and expanding potential treatments across diverse diseases.

  6. Late‑Stage Progress In Excipients For Precision Nanomedicine 5/6/2026

    View late‑stage development and GMP manufacturing of novel excipients for nanomedicines, emphasizing regulatory rigor, process optimization, analytics, and scale‑up for lipid‑based delivery systems.

  7. Solve ATMP Aseptic Filling Challenges With Gloveless Isolators 1/9/2026

    Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.

  8. A Scalable Platform To Revolutionize Gene Therapy Manufacturing 11/22/2024

    Discover how our innovative rAAV production platform can revolutionize your gene therapy pipeline with unparalleled yield, quality, and scalability.

  9. Improvements In ADC Efficacy And Stability 3/17/2026

    Antibody–drug conjugates link antibodies to potent toxins, but increased hydrophobicity impairs stability, manufacturing, and PK, spurring interest in hydrophilic linker strategies.

  10. Developing Pulmonary Dosage Forms For Complex Molecule Delivery 9/23/2025

    Discover how next-generation inhalation technologies can transform pulmonary drug delivery and unlock new therapeutic possibilities for a wide range of respiratory diseases.